ATA3431

ATA3431 is an allogeneic dual CAR T-cell therapy candidate developed by Atara Biotherapeutics. It targets both CD19 and CD20 antigens using a bispecific chimeric antigen receptor (CAR) construct built on an Epstein-Barr virus (EBV)-sensitized T-cell platform. The therapy incorporates a novel 1XX costimulatory domain to enhance expansion and persistence of the CAR T cells while reducing exhaustion. Unlike many other allogeneic CAR-T therapies, ATA3431 retains an unedited native T-cell receptor and does not require gene editing for human leukocyte antigen (HLA) or TCR knockout, leveraging the inherent properties of EBV-sensitized T cells to minimize alloreactivity. The dual targeting approach aims to address antigen escape—a common mechanism of resistance in B-cell malignancies treated with single-targeted CAR-T therapies—by simultaneously recognizing both CD19 and CD20 on malignant B cells. Preclinical studies have shown potent anti-tumor activity, long-term persistence, superior tumor growth inhibition compared to autologous benchmarks, minimal alloreactivity against HLA-mismatched targets, and no observed treatment-related toxicities. Primary indications under development include B-cell malignancies and autoimmune diseases[1][2][3][5][6].